COPD Clinical Trials & Lung Care Advances

About Conference

15^th International Conference on COPD Clinical Trials & Lung Care Advances

October 27–28, 2026 | Paris, France

Transforming COPD Care Through Clinical Excellence and Innovation

Conference Series proudly invites researchers, clinicians, healthcare professionals, academicians, industry experts, and students from around the world to attend the 15^th International Conference on COPD Clinical Trials & Lung Care Advances, scheduled for October 27–28, 2026, in Paris, France.

This international conference will feature Keynote Lectures, Oral Presentations, Poster Sessions, Workshops, Networking Opportunities, and Exhibitions, providing a dynamic platform to discuss the latest developments in COPD research, clinical trials, respiratory medicine, and advanced lung care.

The conference aims to bring together pulmonologists, respiratory specialists, researchers, healthcare providers, pharmaceutical companies, and medical device manufacturers to share knowledge, foster collaborations, and explore innovative approaches to improving patient outcomes.

Why Attend?

• Discover the latest advancements in COPD clinical trials and respiratory care.
• Network with leading pulmonologists, researchers, and healthcare professionals.
• Present your research and gain valuable international exposure.
• Explore innovative therapies, diagnostic tools, and treatment strategies.
• Build collaborations with academic institutions, healthcare organizations, and industry leaders.

Target Audience

• Pulmonologists and Respiratory Specialists
• Researchers and Scientists
• Healthcare Professionals
• Clinical Trial Experts
• Medical Students and Young Researchers
• Pharmaceutical and Biotechnology Companies
• Medical Device Manufacturers
• Academic Institutions and Healthcare Organizations

Sessions/Tracks

Track 1: Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a common lung disease. Having COPD makes it hard to breathe. The most common of these diseases are emphysema and chronic bronchitis.

Chronic bronchitis is inflammation of the lining of the bronchial tubes, which carry air to and from the air sacs (alveoli) of the lungs. It's characterized by daily cough and mucus (sputum) production.

Emphysema is a condition in which the alveoli at the end of the smallest air passages (bronchioles) of the lungs are destroyed as a result of damaging exposure to cigarette smoke and other irritating gases and particulate matter.

• COPD
• Chronic bronchitis
• Emphysema

Track 2: Chronic Bronchitis

Bronchitis is an inflammation of the liner of the bronchial tubes. That’s when the air tubes in your lungs called bronchi get irritated and inflamed, and you've got coughs for a minimum of 3 months a year for two years during a row. Bronchitis may be either acute or chronic. Swelling of the tubes makes it harder for your lungs to maneuver oxygen in and CO2 out of your body.

• COPD Symptoms
• Emphysema
• Mucus

Track 3: Emphysema

Emphysema is a disease of the lungs. It occurs most frequently in smokers, but it also occurs in people that regularly inhale irritants. Emphysema destroys alveoli, which are air sacs within the lungs. The air sacs weaken and eventually break, which reduces the area of the lungs and therefore the amount of oxygen which will reach the bloodstream.

• Bronchitis
• Exhaustion
• Depression
• Fast Heartbeat

Track 4: Asthama

Asthma is a disease of the airways to the lungs. It makes breathing difficult and should make some physical activities challenging or even impossible. Asthma causes the inside walls of the airways, or the bronchial tubes, to become swollen and inflamed. Asthma can't be cured, but its symptoms are often controlled. Because asthma often changes over time, it's vital that you simply work alongside your doctor to trace your signs and symptoms and adjust your treatment as needed.

• Shortness of Breath
• Difficulty Talking
• Fatigue

Track 5: Pulmonary Arterial Hypertension

Pulmonary hypertension could also be a life-threatening condition that gets worse over time, but treatments can help your symptoms so you'll live better with the disease. In one sort of pulmonary hypertension, called pulmonary arterial hypertension (PAH), blood vessels in your lungs are narrowed, blocked or destroyed.

• Sleep Apnea
• Blood clot in the Lungs
• Congestive heart failure

Track 6: Pneumonia

Pneumonia is an infection of the lungs with a variety of possible causes. It can be a serious and life-threatening disease. It happens when an infection causes the air sacs in your lungs (your doctor will call them alveoli) to fill with fluid or pus. That can make it hard for you to inhale enough oxygen to succeed in your bloodstream.

• Contagious
• Walking Pneumonia
• Diarrhea
• Antibiotics

Track 7: Cystic Fibrosis

Cystic fibrosis (CF) may be a serious genetic condition that causes severe damage to the respiratory and digestive systems. This damage often results from a build-up of thick, sticky mucus within the organs. When mucus clogs the lungs, it can become very difficult for an individual to breathe. The thick mucus also allows for germs to thrive and multiply, which may end in infections and inflammation and sometimes results in severe lung damage and respiratory failure.

• Diabetes
• Malnutrition
• Nasal Polyps

Track 8: Coronavirus (COVID-19)

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. COVID-19 is a disease caused by SARS-CoV-2 that can trigger what doctors call a respiratory tract infection. It can affect your upper respiratory tract (sinuses, nose, and throat) or lower respiratory tract (windpipe and lungs).

• Sortness of breath
• Trouble Breathing

Track 9: Lung Cancer

Lung cancer is a type of cancer that starts in the lungs. It is commonest in males, and within the U.S., Black males are around 15% more likely to develop it than white males. People who smoke have the best risk of carcinoma, though carcinoma also can occur in people that haven't smoked.

• Bronchi
• Trachea
• Pleura

Track 10: Interventional pulmonology

Interventional pulmonology (IP) may be a rapidly growing, procedurally focused subspecialty of pulmonary medicine. Interventional pulmonology uses endoscopy and other tools to diagnose and treat conditions within the lungs and chest. Diseases which were previously almost considered as contraindications to bronchoscopy, like asthma and COPD/emphysema, can now, in selected cases, be treated endoscopically.

• Diagnostic Bronchoscopy
• COPD/Emphysema
• Rigid Bronchoscopy

Track 11: Respiratory Tract Infections

Respiratory tract infection (RTI) is defined as any communicable disease of the upper or lower tract. Most RTIs recover without treatment, but sometimes you'll got to see your GP. Upper respiratory tract infections (URTIs) include the common cold, laryngitis, pharyngitis/tonsillitis, acute rhinitis, acute rhinosinusitis and acute otitis media. Lower respiratory tract infections (LRTIs) include acute bronchitis, bronchiolitis, pneumonia and tracheitis.

• Diagnosis
• Antibiotics
• Epidemiology

Track 12: Stages & Severity on Lung Diseases

There is no formal staging system for pulmonary fibrosis. Physicians use different factors, like the ones listed below, to describe the disease as mild, moderate, severe or very severe.

• Symptoms
• Pulmonary Function Test or Lung function Test
• Six minute walk test
• A high resolution CT scan

Market Analysis

The global Chronic Obstructive Pulmonary Disease (COPD) market is expected to reach approximately USD 28–30 billion by 2026, growing at a CAGR of around 5–6%. COPD affects more than 390 million people worldwide and remains one of the leading causes of death globally, accounting for nearly 3.2 million deaths annually.

The increasing prevalence of smoking, air pollution, occupational exposure to harmful particles, and an aging population continue to drive market growth. Among COPD types, Chronic Bronchitis accounts for over 55% of diagnosed COPD cases, making it a major contributor to the market.

North America currently holds the largest market share, while the Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare investments and rising respiratory disease burden. Continued advancements in clinical trials, inhalation therapies, biologics, and digital respiratory care are expected to further strengthen the COPD market in the coming years.